Literature DB >> 30010890

Supra-annular versus intra-annular prostheses in aortic valve replacement: impact on haemodynamics and clinical outcomes.

Sang Hyun Kim1, Ho Jin Kim2, Joon Bum Kim2, Sung-Ho Jung2, Suk Jung Choo2, Cheol Hyun Chung2, Jae Won Lee2.   

Abstract

OBJECTIVES: The superiority of supra-annular aortic prostheses over intra-annular equivalents in long-term haemodynamics and clinical outcomes remains controversial. This study compared outcomes among patients receiving supra-annular or intra-annular prostheses during aortic valve replacement.
METHODS: We enrolled 587 consecutive patients (mean age 55.1 ± 11.3 years; 188 women) undergoing aortic valve replacement with either supra-annular (n = 316) or intra-annular (n = 271) mechanical prostheses between 2000 and 2016 in our institute. Clinical outcomes and haemodynamic profiles in the 2 groups were compared after propensity score adjustment.
RESULTS: Early death (1.1% vs 0.6%; P = 0.863) was equivalent for both groups. Patients receiving supra-annular prostheses showed a lower rate of patient-prosthesis mismatch (1.2% vs 25.8%; P < 0.001). During a median follow-up of 65 months (quartile 1-3, 30-108 months), overall deaths occurred in 84 (14.3%) patients. The latest echocardiographic assessment in the 136 propensity score-matched pairs demonstrated superior haemodynamics with implantation of supra-annular prostheses: peak velocity (2.7 ± 0.6 vs 2.3 ± 0.5 m/s; P < 0.001), mean pressure gradient (16.5 ± 9.0 vs 12.0 ± 6.2 mmHg; P < 0.001) and left ventricular mass index (113.6 ± 30.3 vs 105.3 ± 26.3 g/m2; P = 0.016). After adjusting with inverse-probability-of-treatment weighting, however, the choice of supra-annular over intra-annular prosthesis did not significantly affect the risk of overall mortality (P = 0.693) or major adverse events: stroke (P = 0.944), infective endocarditis (P = 0.958) and reoperation (P = 0.944).
CONCLUSIONS: The implantation of supra-annular prostheses resulted in superior haemodynamics and left ventricular mass regression, while conferring no apparent clinical benefits. Follow-up studies are required to further evaluate the impact of superior haemodynamics associated with supra-annular prostheses on long-term clinical outcomes.

Entities:  

Mesh:

Year:  2019        PMID: 30010890     DOI: 10.1093/icvts/ivy190

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  6 in total

Review 1.  Prosthesis-patient mismatch after transcatheter aortic valve implantation.

Authors:  Masaki Miyasaka
Journal:  Cardiovasc Interv Ther       Date:  2022-06-16

2.  Incidence and impact of prosthesis-patient mismatch following transcatheter aortic valve implantation.

Authors:  Hatim Seoudy; Nathalie Güßefeld; Johanne Frank; Sandra Freitag-Wolf; Georg Lutter; Matthias Eden; Ashraf Yusuf Rangrez; Christian Kuhn; Norbert Frey; Derk Frank
Journal:  Clin Res Cardiol       Date:  2018-11-19       Impact factor: 5.460

3.  Determinants of effective orifice area in aortic valve replacement: anatomic and clinical factors.

Authors:  Hee Jung Kim; Sung Jun Park; Hyun Jung Koo; Joon-Won Kang; Dong Hyun Yang; Sung-Ho Jung; Suk Jung Choo; Cheol Hyun Chung; Jae Won Lee; Joon Bum Kim
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

4.  Mid-term outcomes of patients with Lotus and Evolut transcatheter valves.

Authors:  Petr Hájek; Eva Polaková; Radka Adlová; Martin Horváth; Eva Hansvenclová; Monika Pecková; Josef Veselka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2022-08-19       Impact factor: 1.065

Review 5.  Multimodality Imaging of the Anatomy of the Aortic Root.

Authors:  Vera Lucia Paiocchi; Francesco F Faletra; Enrico Ferrari; Susanne Anna Schlossbauer; Laura Anna Leo; Francesco Maisano
Journal:  J Cardiovasc Dev Dis       Date:  2021-05-04

6.  In vitro comparison of everting vs. non-everting suture techniques for the implantation of a supra-annular biological heart valve.

Authors:  Nazan Puluca; Andrea Münsterer; Anatol Prinzing; Zachary A Sexton; Rüdiger Lange; Roza Meyer-Saraei; Michael Scharfschwerdt
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.